| Drug Name: | Vigabatrin (60643-86-9) |
|---|---|
| PubChem ID: | 5665 |
| SMILES: | C=CC(CCC(=O)O)N |
| InchiKey: | PJDFLNIOAUIZSL-UHFFFAOYSA-N |
| Therapeutic Category: | Anticonvulsants, Central Nervous System Agents, Enzyme Inhibitors, GABA Agents, Neurotransmitter Agents |
| Molecular Weight (dalton) | : | 129.159 |
| LogP | : | 0.3645 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 63.32 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Phenytoin (57-41-0) | Increase In Seizure Frequency | Antagonistic | Not understood | A multicentre study of vigabatrin for drug-resistant epilepsy |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category